Roche hands Chi­nese biotech $70M for HER2 drug that can go to the brain

Roche is still hunt­ing for next-gen­er­a­tion drugs that can hit HER2-pos­i­tive can­cer, and it’s found a Phase I can­di­date it likes from a Chi­nese biotech.

The Swiss phar­ma gi­ant will pay Zion Phar­ma $70 mil­lion in up­front and near-term mile­stones to get its hands on an oral HER2 ty­ro­sine ki­nase in­hibitor.

HER2, or the hu­man epi­der­mal growth fac­tor re­cep­tor 2, is an in­creas­ing­ly pop­u­lar tar­get for can­cer drug­mak­ers, with As­traZeneca, Seagen and many oth­er biotechs bet­ting on new mol­e­cules.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.